Snake Venom-specific Phospholipase A2: A Diagnostic Marker for the Management of Snakebite Cases.
Antivenom
Enzyme
Snakebite
Venom
Venom-specific phospholipase A2
Journal
Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine
ISSN: 0972-5229
Titre abrégé: Indian J Crit Care Med
Pays: India
ID NLM: 101208863
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
14
10
2022
accepted:
21
10
2022
entrez:
9
2
2023
pubmed:
10
2
2023
medline:
10
2
2023
Statut:
ppublish
Résumé
Snakebites are a common cause of morbidity and mortality, especially in tropical countries. Snakebites in any community are managed based on the clinical features and intravenous administration of antisnake venom (ASV). The administration of ASV is either deficient or given in excess based on clinical decisions and whole blood clotting test results. The present study is designed to analyze the level of snake venom component in the blood of snakebite in association with the clinical features. Blood samples were collected from the patients admitted to Karnataka Institute of Medical (KIMS) hospital with a history of snakebite considering the inclusion criteria. Serum was collected from the blood of snakebite patients before and after ASV and used to assess the level of venom-specific phospholipase A2 (PLA2) enzyme using the enzyme-linked immunosorbent assay (ELISA) method. Quantitative ELISA results revealed that the snake venom-specific PLA2 in the victim's blood was in the range of 0.3-1.27 mg/mL before the administration of ASV. However, the concentration of PLA2 after 24 hours of ASV administration was decreased in most of the patients. Further, it was observed that envenomation complications were directly proportional to the amount of snake venom-specific PLA2 found in the blood of the snakebite patient. The study concludes that snake venom-specific PLA2 in the blood of snakebite patients could be used as a reliable venom marker, which helps in determination of appropriate ASV dosage in snakebite patients. Kaulgud RS, Hasan T, Vanti GL, Veeresh S, Uppar AP, Kurjogi MM. Snake Venom-specific Phospholipase A2: A Diagnostic Marker for the Management of Snakebite Cases. Indian J Crit Care Med 2022;26(12):1259-1266.
Sections du résumé
Background
UNASSIGNED
Snakebites are a common cause of morbidity and mortality, especially in tropical countries. Snakebites in any community are managed based on the clinical features and intravenous administration of antisnake venom (ASV). The administration of ASV is either deficient or given in excess based on clinical decisions and whole blood clotting test results. The present study is designed to analyze the level of snake venom component in the blood of snakebite in association with the clinical features.
Patients and methods
UNASSIGNED
Blood samples were collected from the patients admitted to Karnataka Institute of Medical (KIMS) hospital with a history of snakebite considering the inclusion criteria. Serum was collected from the blood of snakebite patients before and after ASV and used to assess the level of venom-specific phospholipase A2 (PLA2) enzyme using the enzyme-linked immunosorbent assay (ELISA) method.
Results
UNASSIGNED
Quantitative ELISA results revealed that the snake venom-specific PLA2 in the victim's blood was in the range of 0.3-1.27 mg/mL before the administration of ASV. However, the concentration of PLA2 after 24 hours of ASV administration was decreased in most of the patients. Further, it was observed that envenomation complications were directly proportional to the amount of snake venom-specific PLA2 found in the blood of the snakebite patient.
Conclusion
UNASSIGNED
The study concludes that snake venom-specific PLA2 in the blood of snakebite patients could be used as a reliable venom marker, which helps in determination of appropriate ASV dosage in snakebite patients.
How to cite this article
UNASSIGNED
Kaulgud RS, Hasan T, Vanti GL, Veeresh S, Uppar AP, Kurjogi MM. Snake Venom-specific Phospholipase A2: A Diagnostic Marker for the Management of Snakebite Cases. Indian J Crit Care Med 2022;26(12):1259-1266.
Identifiants
pubmed: 36755629
doi: 10.5005/jp-journals-10071-24362
pmc: PMC9886021
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1259-1266Informations de copyright
Copyright © 2022; Jaypee Brothers Medical Publishers (P) Ltd.
Déclaration de conflit d'intérêts
Source of support: Nil Conflict of interest: None
Références
Toxicon X. 2021 Dec 18;13:100089
pubmed: 35005609
PLoS Negl Trop Dis. 2010 Jan 26;4(1):e603
pubmed: 20126271
Sci Rep. 2016 May 27;6:26778
pubmed: 27231196
Toxicon. 2015 Jan;93:112-8
pubmed: 25447776
J Occup Med Toxicol. 2018 Aug 15;13:26
pubmed: 30147746
Br J Clin Pharmacol. 2016 Mar;81(3):446-52
pubmed: 26256124
Toxins (Basel). 2018 Nov 02;10(11):
pubmed: 30400220
Sci Rep. 2014 Apr 29;4:4827
pubmed: 24777205
PLoS Negl Trop Dis. 2011 Apr 12;5(4):e1018
pubmed: 21532748
PLoS Med. 2008 Nov 4;5(11):e218
pubmed: 18986210
BMJ. 2013 Jan 31;346:f628
pubmed: 23369843
J Proteomics. 2011 Aug 24;74(9):1735-67
pubmed: 21640209
Indian J Crit Care Med. 2015 Jun;19(6):340-9
pubmed: 26195860
Toxicon. 1974 Mar;12(2):167-71
pubmed: 4852085
Wilderness Environ Med. 2009 Spring;20(1):43-56
pubmed: 19364169
Toxicol Rep. 2017 Nov 24;5:1-5
pubmed: 29234603
Proc Biol Sci. 2009 Jul 7;276(1666):2443-9
pubmed: 19364745
Indian J Crit Care Med. 2014 Mar;18(3):123-4
pubmed: 24701058
Bull World Health Organ. 1998;76(5):515-24
pubmed: 9868843
Toxins (Basel). 2019 Jun 20;11(6):
pubmed: 31226842
Trans R Soc Trop Med Hyg. 2008 Nov;102(11):1108-14
pubmed: 18501936
J Clin Diagn Res. 2013 Jan;7(1):122-6
pubmed: 23450135
BMC Genomics. 2011 May 23;12:259
pubmed: 21605378
Lancet. 2018 Aug 25;392(10148):673-684
pubmed: 30017551
Toxicol Int. 2014 May;21(2):203-8
pubmed: 25253932
J Proteomics. 2016 Mar 1;135:73-89
pubmed: 25968638
Toxins (Basel). 2017 Sep 18;9(9):
pubmed: 28927001
PLoS Negl Trop Dis. 2020 Oct 5;14(10):e0008668
pubmed: 33017411